Introduction
Opioid receptors (ORs) are G-protein Coupled Receptors (GPCRs), which mediate analgesia, tolerance, withdrawal, GI transit. Classically, ORs couple inhibitory Gi/o proteins and recruit -arrestin -a multifaceted scaffold molecule implicated in opioid mediated effects including tolerance, constipation, dysphoria and naseua [1, 2] . Upon activation -arrestin and Gi/o induce downstream signaling responses such as reduced cAMP levels. Recent drug discovery efforts identified several functionally selective exogenous opiates which prefer certain signaling pathways at a given receptorsuch as G stimulation -to others -such as -arrestin recruitment and generate desired pharmacological properties [3, 4] . Noting that most of the 20+ endogenous opioid peptides are nonselective and some opiates display functional selectivity, two important points emerge. First, endogenous and exogenous ligands, such as those used during studies, do not necessarily generate the same effects. Second, two different endogenous opioid peptides may differentially activate a given receptor. Dynorphin A (DynA) and Dynorphin B (DynB) are considered OR agonists, despite binding to the OR at 1.29nM and 3.39 nM [1] , respectively. The Dynorphins start with the 5 amino acid Leuenkephalin (Leu-Enk) sequence -YGGFL -traditionally considered a OR agonist followed by distinct C-terminal sequences. Thus, we ask: Do Dynorphin A (1-17), Dynorphin B (1-13) and Leuenkephalin induce functionally selective signaling at the OR?
Results and Discussion
We assessed DynA, DynB and Leu-Enk signaling for two ubiquitous GPCR signals -G activation and -arrestin recruitment -in vitro. GTPS stimulation assays were performed using CHO cells expressing the OR, analogous to previous reports [5] . -Arrestin-2 recruitment assays (DiscoveRx) were performed by manufacturer's protocol. We found DynA, DynB and Leu-Enk display different potency rank orders for G activity and -arrestin recruitment at the OR (Table 1 Next we probed each ligand for forskolin-stimulated cAMP inhibition -a well-established G dependent pathway [6] . Acute treatment of DynA and Leu-Enk yield IC50 values of 21 nM and 5nM, respectively (Table 1) . However, DynB exhibits a ~10 fold less potent response (IC50=122 nM). DynB is a less potent agonist in the forskolin induced cAMP inhibition compared to DynA and Leu-Enk, whereas all display similar potency in the GTPS assay. Based on differential cAMP inhibition potencies and efficacies, we predicted these peptides would differentially effect receptor mediated G regulation. At the OR, chronic opioid treatment causes a compensatory increase in basal cAMP levels, referred to as Adenylyl Cyclase (AC) super activation. AC super activation may play a physiological role in developing opioid tolerance, dependence and withdrawal [5, 6] . Chronic treatment with DynA led to greater AC super activation than treatment with DynB or Leu-Enk, which similarly induce AC super activation (Figure 1 ). This upregulation in forskolin-stimulated cAMP indicates that DynA and DynB induce distinct receptor regulatory events. Differences in AC super activation by endogenous ligands could be important in the physiological roles of disease and require further in vivo study. Thus, in vitro assays show endogenous opioid peptides with differing (or absent) C-terminal tails induce distinct changes in the activity of these peptides. Therefore, we show three endogenous opioids induce distinct signaling and regulatory outcomes in vitro. Further studies are required to understand the differences in G activation, other cellular regulatory changes and potential uses as a peptide scaffold for drug design. 
